A5073594523- SARS-CoV-2 and COVID-19 Research
- Immunotherapy and Immune Responses
- Peripheral Neuropathies and Disorders
- Animal Virus Infections Studies
- Retinal and Optic Conditions
- T-cell and B-cell Immunology
- Viral gastroenteritis research and epidemiology
- Heparin-Induced Thrombocytopenia and Thrombosis
- Viral Infections and Immunology Research
- Intramuscular injections and effects
- Bacterial Infections and Vaccines
- Immunodeficiency and Autoimmune Disorders
- Respiratory viral infections research
- Multiple Sclerosis Research Studies
- COVID-19 Clinical Research Studies
Humboldt-Universität zu Berlin
2022-2024
Charité - Universitätsmedizin Berlin
2022-2024
Freie Universität Berlin
2022-2024
Objective The development of sufficient COVID-19 vaccines has been a big breakthrough in fighting the global SARS-CoV-2 pandemic. However, vaccination effectiveness can be reduced patients with autoimmune rheumatic diseases (AIRD). aim this study was to identify factors that lead diminished humoral response AIRD. Methods Vaccination measured surrogate virus neutralisation test and by testing for antibodies directed against receptor-binding-domain (RBD) 308 fully vaccinated In addition, 296...
Objective The level of neutralising capacity against Omicron BA.1 and BA.2 after third COVID-19 vaccination in patients on paused or continuous methotrexate (MTX) therapy is unclear. Methods In this observational cohort study, serum activity SARS-CoV-2 wild-type (Wu01) variant concern were assessed by pseudovirus neutralisation assay before, 4 12 weeks mRNA booster immunisation 50 rheumatic MTX, 26 whom the medication. 44 non-immunosuppressed persons (NIP) served as control group. Results...
Abstract Active and passive immunization is used in high‐risk patients to prevent severe courses of COVID‐19, but the impact prophylactic neutralizing antibodies on immune reaction mRNA vaccines has remained enigmatic. Here we show that CD4 T B cell responses Spikevax booster are suppressed by therapeutic Casirivimab Imdevimab. were significantly induced controls not antibody‐treated patients. The data indicates humoral immunity, i. e. high levels antibodies, negatively impacts reactive...
ABSTRACT Objective To determine the immediate need for a fourth COVID-19 vaccination based on neutralizing capacity in patients methotrexate (MTX) therapy after mRNA booster immunization. Methods In this observational cohort study, serum activity against SARS-CoV-2 wildtype (Wu01) and variant of concern (VOC) Omicron BA.1 BA.2 were assessed by pseudovirus neutralization assay before, 4 12 weeks immunization 50 rheumatic MTX, 26 whom paused medication. 44 non-immunosuppressed persons (NIP)...
Background: The level of neutralizing capacity against Omicron BA.1 and BA.2 after third COVID-19 vaccination in patients on paused or continuous MTX therapy is unclear.Methods: In this observational cohort study, serum activity SARS-CoV-2 wildtype (Wu01) variant concern (VOC) were assessed by pseudovirus neutralization assay before, 4 12 weeks mRNA booster immunization 50 rheumatic MTX, 26 whom the medication. 44 non-immunosuppressed persons (NIP) served as control group.Findings: While...
Objective: To determine whether repeated, dose-intensified mRNA vaccinations against COVID-19 increases humoral immunity in previously low-responding patients with autoimmune rheumatic diseases (AIRD), including rituximab-treated and B cell depleted patients.Methods: Of 308 AIRD receiving basic immunization, 98 had a low serological response SARS-CoV-2 neutralizing capacity of < 70% using surrogate neutralization assay. 38 received third vaccination 30 µg BNT162b2 16 weeks after second...